Direct Oral Anticoagulants in the Obese Population: Does One Size Fit All?

<p>Joseph Zieminski, Pharm.D. observed in the obese population, discusses pharmacokinetic changes and outcomes data of direct oral anticoagulants (DOACs) in obese patients and selects an appropriate DOAC for use in an obese patient case.</p> <p>For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs <a href='https://twitter.com/MayoPharmRes'>@MayoPharmRes</a> or the host, Garrett E. Schramm, Pharm.D., <a href='https://twitter.com/garrett_schramm'>@garrett_schramm</a> on Twitter!</p> <p>You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at <a href='https://ce.mayo.edu/'>https://ce.mayo.edu/</a> or on Twitter <a href='https://twitter.com/MayoMedEd'>@MayoMedEd</a>. </p>